Skip to content

logo

የኢትዮጵያ ምግብና መድኃኒት ባለስልጣን
Ethiopian Food and Drug Authority
  • enEnglish
  • amhአማርኛ
 

FacebookTwitterLinkedin
EFDA
Ethiopian Food and Drug Administration
EFDA
  • Home
  • About Us
    • About EFDA
    • Our Vision, Mission and Objectives
    • Organizational Structure
    • Accreditations
    • Power & Duties
      • Gallery
  • News and Events
  • Services
    • Our Services
    • e-service
    • Traceability
      • FAQ’s
    • Electronic Regulatory Information System(eRIS)
    • e-Reporting of ADR
    • Food Rapid Alert
  • Publications
    • All Publications
    • Policies, Legislation And Regulation
      • Policies
      • Proclamations
      • Regulations
    • Directives and Guidelines
      • Medicine Directives
      • Medical Device Guidelines
      • Medicine Guidelines
      • Cosmetic Directive
      • Food Directives
      • Pharmacovigilance
      • Clinical Trials
    • Strategies
    • Manuals
    • Drugs lists and formularies
      • Drug Lists
      • Drug Formulary
    • Bulletins and Newsletter
      • Drug Bulletin
      • Food Bulletin
      • Pharmacovigilance Newsletter
    • Ethiopian public assessment report
    • Ethiopian Traceability System
  • Directorates
    • All Directorates
    • Medicine Registration and Licensing Directorate
    • Medicine Facility Inspection Directorate
    • Food Registration and Licensing Directorate
    • Food Facility Inspection Directorate
    • Food Institution Inspection Directorate
    • Medicine Quality Assessment Directorate
    • Food Quality Assessment Directorate
    • Product Safety Directorate
  • COVID19
    • COVID19 FAQ’s
    • COVID19 publications
    • COVID-19 Quick Access
    • Privacy Policy
  • Announcement
    • Tender
    • Notices
    • Vacancy
  • Contact
    • Uncategorized
  • Home
  • About Us
    • About EFDA
    • Our Vision, Mission and Objectives
    • Organizational Structure
    • Accreditations
    • Power & Duties
      • Gallery
  • News and Events
  • Services
    • Our Services
    • e-service
    • Traceability
      • FAQ’s
    • Electronic Regulatory Information System(eRIS)
    • e-Reporting of ADR
    • Food Rapid Alert
  • Publications
    • All Publications
    • Policies, Legislation And Regulation
      • Policies
      • Proclamations
      • Regulations
    • Directives and Guidelines
      • Medicine Directives
      • Medical Device Guidelines
      • Medicine Guidelines
      • Cosmetic Directive
      • Food Directives
      • Pharmacovigilance
      • Clinical Trials
    • Strategies
    • Manuals
    • Drugs lists and formularies
      • Drug Lists
      • Drug Formulary
    • Bulletins and Newsletter
      • Drug Bulletin
      • Food Bulletin
      • Pharmacovigilance Newsletter
    • Ethiopian public assessment report
    • Ethiopian Traceability System
  • Directorates
    • All Directorates
    • Medicine Registration and Licensing Directorate
    • Medicine Facility Inspection Directorate
    • Food Registration and Licensing Directorate
    • Food Facility Inspection Directorate
    • Food Institution Inspection Directorate
    • Medicine Quality Assessment Directorate
    • Food Quality Assessment Directorate
    • Product Safety Directorate
  • COVID19
    • COVID19 FAQ’s
    • COVID19 publications
    • COVID-19 Quick Access
    • Privacy Policy
  • Announcement
    • Tender
    • Notices
    • Vacancy
  • Contact
    • Uncategorized

Archives:

You are here:
  1. Home
  2. Publication
  3. Page 2

Summary of product characteristics for Isoniazid 100mg and 300mg tablets

By EFDAOctober 10, 2022

Summary of product characteristics for Isoniazid 100mg and 300mg tablets

Public assessment summary report for Isoniazid 100 and 300 mg tablets

By EFDAOctober 10, 2022

Public assessment summary report for Isoniazid 100 and 300 mg tablets

Hemlibra_Emicizumab_ Summary of product characteristics v1

By EFDAApril 6, 2022

Hemlibra_Emicizumab_ Summary of product characteristics v1

Hemlibra_Emicizumab_ Public assessment summary reportv1

By EFDAApril 6, 2022

Hemlibra_Emicizumab_ Public assessment summary reportv1

Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_public assessment summary report

By EFDAMarch 21, 2022

Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_public assessment summary report

Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_Summary of product characteristics

By EFDAMarch 21, 2022

Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_Summary of product characteristics

INIGAST 40 Public assessment summary report v1

By EFDADecember 15, 2021

INIGAST 40 Public assessment summary report v1

INIGAST 40 Summary of product characteristics v1

By EFDADecember 15, 2021

INIGAST 40 Summary of product characteristics v1

ALLTERA 50 Summary of product characteristics v1

By EFDADecember 15, 2021

ALLTERA 50 Summary of product characteristics v1

ALLTERA 50 Public assessment summary report v1

By EFDADecember 15, 2021

ALLTERA 50 Public assessment summary report v1

12
EFDA
Copyright © All rights reserved. EFDA.
Go to Top